New hope for advanced cancers: experimental drug combo targets tough tumors

NCT ID NCT06091930

First seen Oct 01, 2025 · Last updated Apr 24, 2026 · Updated 23 times

Summary

This study tests an experimental drug (BI 765049) alone or with another drug (ezabenlimab) in Asian adults with advanced cancers like stomach, lung, pancreatic, colorectal, head and neck, or liver cancer. The goal is to find the highest safe dose and see if the drugs can shrink tumors. Participants must have tumors with a specific marker called B7-H6 and have tried other treatments without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, 135-8550, Japan

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, 104-0045, Japan

  • National Cancer Center Hospital East

    Chiba, Kashiwa, 277-8577, Japan

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • Shanghai East Hospital

    Shanghai, 200120, China

Conditions

Explore the condition pages connected to this study.